Dr. Sara Tolaney on Cabozantinib in Breast Cancer

Video

In Partnership With:

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.

Sara M. Tolaney, MD, MPH, Instructor in Medicine, Harvard Medical School, Medical Oncologist, Clinical Investigator, Dana-Farber Cancer Institute and Brigham and Women's Hospital, discusses trials investigating cabozantinib in breast cancer.

Cabozantinib is a multi-targeted tyrosine kinase inhibitor aimed at mutations in MET, VEGFR2, and RET. It was recently approved for the treatment of metastatic medullary thyroid cancer and is being explored as a therapy for numerous tumor types, including breast cancer.

In a phase II randomized discontinuation trial, which Tolaney highlights, cabozantinib showed a 14% rate of objective tumor regression in patients with heavily pretreated metastatic breast cancer. There is some rationale, Tolaney says, to analyze cabozantinib in ER-positive breast cancer with bone metastases, due to impressive bone scans and bone pain responses in the trial.

Additionally, Tolaney states, there is reason to explore cabozantinib in patients with triple-negative breast cancer (TNBC) since MET, a target for cabozantinib, is often overexpressed to a higher degree in TNBC than in ER-positive breast cancer.

Related Videos
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD
Shruti Tiwari, MD
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO